INM Stock Overview
A clinical stage pharmaceutical company, develops a pipeline of prescription-based products.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
InMed Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$2.08 |
| 52 Week Low | US$0.23 |
| Beta | 0.53 |
| 1 Month Change | 14.92% |
| 3 Month Change | -26.41% |
| 1 Year Change | -76.48% |
| 3 Year Change | -99.58% |
| 5 Year Change | -99.87% |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02InMed's INM-755 CBN cream did not introduce any delay in normal wound healing
Jan 08Shareholder Returns
| INM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.8% | -0.8% | -1.2% |
| 1Y | -76.5% | 14.8% | 21.5% |
Return vs Industry: INM underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: INM underperformed the US Market which returned 25.2% over the past year.
Price Volatility
| INM volatility | |
|---|---|
| INM Average Weekly Movement | 12.2% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: INM's share price has been volatile over the past 3 months.
Volatility Over Time: INM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Eric Adams | www.inmedpharma.com |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products.
InMed Pharmaceuticals Inc. Fundamentals Summary
| INM fundamental statistics | |
|---|---|
| Market cap | US$1.91m |
| Earnings (TTM) | -US$6.08m |
| Revenue (TTM) | US$5.63m |
0.3x
P/S Ratio-0.3x
P/E RatioIs INM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INM income statement (TTM) | |
|---|---|
| Revenue | US$5.63m |
| Cost of Revenue | US$3.42m |
| Gross Profit | US$2.21m |
| Other Expenses | US$8.28m |
| Earnings | -US$6.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 39.20% |
| Net Profit Margin | -108.01% |
| Debt/Equity Ratio | 0% |
How did INM perform over the long term?
See historical performance and comparison